Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
GMAB · Nasdaq · United States · Pharmaceutical Preparations
In shortGENMAB A/S is profitable.
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | – | n/a |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | – | n/a |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 23.0% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 5.25× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | n/a |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | – | n/a |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | – | n/a |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 0.99× | 86/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 2 | 100/100 |
| Revenue growth volatility | 35.0% | 0/100 |
| Operating margin volatility | 5.7% | 57/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | – | n/a |
|---|---|---|
| EPS growth, 3-year average | 72.3% | 100/100 |
Weight in the score: 10%
Fiscal year 2024 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
The last 5 fiscal years from the company's annual reports.
DKK millions; negative values in parentheses.
| Fiscal year | FY17 | FY18 | FY19 | FY23 | FY24 |
|---|---|---|---|---|---|
| Revenue | 2,365 | 3,025 | 5,366 | – | – |
| Research & development | 874 | 1,431 | 2,386 | – | – |
| Operating income | 1,344 | 1,380 | 2,638 | – | – |
| Interest expense | 352 | 11 | 7 | – | – |
| Pre-tax income | 1,064 | 1,612 | 2,859 | – | – |
| Income tax | (40) | 140 | 693 | – | – |
| Net income | 1,104 | 1,472 | 2,166 | 4,352 | 7,844 |
| Diluted EPS | kr17.77 | kr23.73 | kr34.03 | kr66.02 | kr121.36 |
| Diluted shares (millions) | 62 | 62 | 64 | 66 | 65 |
Not computed: a required balance-sheet item is missing.
5/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice.
Latest annual report: Dec 31, 2025 · Data updated Feb 17, 2026